Related Experiment Video

Updated: Aug 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ineffectiveness of lipid-lowering therapy in primary care

E Van Ganse1, T Souchet, L Laforest

  • 1Pharmacoepidemiology, EA3091, CHU-Lyon, France. eric-vanganse@chu-lyon.fr

British Journal of Clinical Pharmacology
|April 2, 2005
PubMed

Insights

Lipid-lowering agent adherence to French guidelines for LDL-cholesterol targets decreases as cardiovascular risk increases. Many patients not at goal are undertreated, limiting cardiovascular disease protection.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Lipid-lowering agents are crucial for managing cardiovascular disease (CVD) risk.
  • French guidelines (AFSSAPS) set LDL-cholesterol targets based on CVD risk factors.
  • Understanding guideline adherence across risk strata is essential for optimizing CVD prevention.

Purpose of the Study:

  • To assess the proportion of dyslipidaemic patients achieving LDL-cholesterol goals under French guidelines.
  • To evaluate if adherence to lipid-lowering therapy guidelines varies with cardiovascular risk level.
  • To compare adherence with French (AFSSAPS) and international (ANDEM) guidelines.

Main Methods:

  • A cohort of 3173 French patients on lipid-lowering agents was analyzed.
  • Cardiovascular risk factors and history of coronary heart disease were documented.
  • Achievement of LDL-cholesterol therapeutic objectives determined guideline compliance.

Main Results:

  • Primary prevention patients (79%) showed increasing LDL-cholesterol goal failure with higher risk (3.9% to 46.5%).
  • Secondary prevention patients experienced a 39.9% therapeutic failure rate under AFSSAPS guidelines.
  • A significant proportion of high-risk patients not at goal received suboptimal lipid-lowering agent doses; 74% of secondary prevention patients missed goals per ANDEM guidelines.

Conclusions:

  • Guideline compliance for lipid-lowering therapy is inversely related to cardiovascular risk.
  • Patients failing to reach LDL-cholesterol targets are frequently not prescribed intensified treatment (up-titrated).
  • Current use of lipid-lowering agents appears inadequate, potentially compromising CVD protection for many patients.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...